Amgen (AMGN) says FDA extended review period for Lumakras in combination with Vectibix for treating some colorectal cancer patients
- FDA shifted the PDUFA date by 3 months to Jan 17, 2025 to allow additional time for review of supplemental data recently submitted to agency
18 Oct 2024 - 13:22- Equities- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts